- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00361218
Biological Markers of Response to Treatment in Major Depressive Disorder
Serum Brain-Derived Neurotrophic Factor (BDNF) and QEEG as Biological Markers of Response to (Es)Citalopram Treatment in Major Depressive Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Major depressive disorder (MDD) is a severe form of depression. MDD can significantly interfere with an individual's thoughts, behavior, mood, and physical health. People who suffer from MDD often experience feelings of worthlessness; they may feel hopeless and may be unable to cope with problems in their life. In addition, they often experience sleep disruption, loss of appetite, and chronic pain.
It often takes several weeks to find out if an antidepressant medication is going to work for someone. This research study aims to identify tests that are able to predict if a medication will work, even before a person starts to feel better. The first test is a measurement of the blood protein Brain-Derived Neurotrophic Factor (BDNF), which is involved with brain cell growth. The second test is a Quantitative Electroencephalogram (QEEG), which measures brain activity.
The study lasts for 8 weeks and involves 5 total visits to the clinic. Throughout the study, all subjects will receive either escitalopram (Lexapro) or citalopram (Celexa) on the basis of the study doctor's clinical judgment. The dose of the medications can be increased at any point in time if the study doctor thinks it is appropriate. After the first screen visit (which lasts about 3 hours), each subsequent half-hour visit will involve a 2-tablespoon blood draw to measure BDNF levels, as well as a QEEG in which small, painless electrodes are stuck to the subject's forehead and electrical activity of the brain is measured. At the end of the 8 weeks, subjects are offered 3 months of free follow-up care, including medications.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ages 18-65
- Meet criteria for current Major Depressive Disorder
- Antidepressant medication-free for at least 2 weeks prior to the start of the study
Exclusion Criteria:
- Pregnant or breastfeeding women
- Anyone who is suicidal
- Anyone with an unstable medical condition (cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological), substance abuse problem within the past 6 months, psychoses (past or current), hypothyroidism, or hypomania
- Anyone currently taking an SSRI
- Past intolerance to Lexapro or Celexa
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: open-label selective serotonin reuptake inhibitor (SSRI)
citalopram or escitalopram
|
Duration is 8 weeks.
For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion.
For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Brain-derived Neurotrophic Factor (BDNF) Levels
Time Frame: 8 weeks
|
"Pre-SSRI BDNF Level" refers to the data collection point before SSRI intake and "Post-SSRI BDNF Level" refers to the data collection point 8 weeks after SSRI intake.
|
8 weeks
|
Quantitative Electroencephalogram (QEEG) Parameters as Predictors of Response
Time Frame: 8 weeks
|
Pre-treatment quantitative electroencephalogram (QEEG) refers to the data collection point before selective serotonin reuptake inhibitor (SSRI) treatment and Post-treatment QEEG refers to the data collection point 8 weeks after SSRI treatment initiation. Response refers to a greater than 50% decrease in Hamiton Depression Rating Scale from baseline, which ranges from 0 (no depression) to a maximum of 54 (severe depression). |
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John Denninger, MD, PhD, Depression Clinical and Research Program, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Serotonin Receptor Agonists
- Antidepressive Agents, Second-Generation
- Citalopram
- Serotonin
- Serotonin Uptake Inhibitors
Other Study ID Numbers
- 2005P000413
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on open-label selective serotonin reuptake inhibitor (SSRI)
-
Ohio State UniversityWithdrawnDementia | Alzheimer Disease | Mild Cognitive ImpairmentUnited States
-
VA Office of Research and DevelopmentNot yet recruitingTraumatic Brain Injury (TBI)United States
-
Eli Lilly and CompanyBoehringer IngelheimCompletedDiabetes Mellitus, Type 2India, Turkey, United States, Puerto Rico, Taiwan, Korea, Republic of, Russian Federation
-
University GhentUniversity Hospital, GhentCompletedDepressive Disorder, Major | Treatment Resistant Depression | MelancholiaBelgium
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited Kingdom, United States, Belgium, Austria, Australia, Germany, Sweden
-
Eli Lilly and CompanyCompletedMajor Depressive Disorder (MDD)United States, Puerto Rico, Finland, Japan, Slovakia, Czechia, Croatia
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited States, Germany, Italy, Turkey, Russian Federation, Korea, Republic of, Greece, France, Croatia, Romania, Spain, Argentina, Puerto Rico, Belgium, Mexico, Slovakia
-
Hospital Clinic of BarcelonaCompleted
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited States, South Africa, Poland, Ukraine, Japan, Russian Federation, Latvia
-
The Cleveland ClinicCompletedBipolar Disorder | Major DepressionUnited States